-+ 0.00%
-+ 0.00%
-+ 0.00%

AGENUS REPORTS 48% ESTIMATED THREE-YEAR SURVIVAL WITH BOT+BAL IN RECURRENT OVARIAN CANCER AT IGCS 2026

Reuters·10/03/2026 14:50:03

Please log in to view news